Ashland swung back to profitability in Q3 2026 with earnings per share of $0.35 driven primarily by higher sales volumes despite persistent cost inflation and competitive pricing pressure [S2][N1][N6]. The company reaffirmed full-year sales guidance, reflecting resilience supported by its diversified portfolio spanning Life Sciences, Personal Care, Specialty Additives, and Intermediates [S2][S1]. While volume growth bolsters revenue, Ashland continues to manage significant environmental remediation liabilities estimated at $226 million, representing a material constraint on cash flow and margin expansion [S1][S2]. New board appointments suggest a governance refresh aimed at optimizing asset utilization amid ongoing strategic execution challenges [S3]. Going forward, demand drivers centered on sustainability trends and emerging market expansion present growth opportunities balanced against regulatory risks and supply chain complexities.